Embion Technologies SA Revenue and Competitors
Estimated Revenue & Valuation
- Embion Technologies SA's estimated annual revenue is currently $1.4M per year.
- Embion Technologies SA's estimated revenue per employee is $155,000
Employee Data
- Embion Technologies SA has 9 Employees.
- Embion Technologies SA grew their employee count by -40% last year.
Embion Technologies SA's People
Name | Title | Email/Phone |
---|
Embion Technologies SA Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Embion Technologies SA?
EMBION catalyzes the future of #nutrition by introducing a portfolio of sophisticated, complex EMBION-BIOACTIVES with expanded prebiotic properties. EMBION innovates with brilliant #plant-based technologies that customize unique nutrition in exceptional speed and are surprisingly affordable.
keywords:N/AN/A
Total Funding
9
Number of Employees
$1.4M
Revenue (est)
-40%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Embion Technologies SA News
2022-04-13 - Human Microbiome Therapeutics Market Products, Share, Growth, Insights and Forecasts Report 2027
... BiomX Ltd., LNC Therapeutics SA, Commense Inc, Embion Technologies SA, DermBiont, Inc, CoreBiome, Inc., Carbiotix AB, Biotagenics Inc.,...
2022-04-06 - Human Microbiome Therapeutics Market Overview Highlighting ...
Key participants include Oxidien Pharmaceuticals, LLC, BiomX Ltd., LNC Therapeutics SA, Commense Inc, Embion Technologies SA, DermBiont,...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.7M | 9 | N/A | N/A |
#2 | $3.6M | 21 | 11% | N/A |
#3 | $5.9M | 41 | 24% | N/A |
#4 | $8.7M | 56 | 30% | N/A |
#5 | $19.3M | 66 | 29% | N/A |